Funding for this research was provided by:
National Institute on Drug Abuse (K01DA043412, R01DA051849)
Received: 9 June 2022
Accepted: 26 January 2023
First Online: 7 February 2023
: The study protocol was approved by the Boston Medical Center Institutional Review Board. Per IRB approval, obtained verbal informed consent was obtained from study participants prior to initiating any study activities.
: Not applicable.
: Dr. Biello reports receiving unrestricted research funds from Merck outside of the submitted work. The other authors have no conflicts of interest to declare.